Intensity Therapeutics (INTS) Stock Price, News & Analysis

Company Overview

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company developing cancer immunotherapies designed to treat solid tumors. The company’s approach is based on its proprietary INTASYL technology, which is intended to enable therapeutic compounds to enter tumor cells directly, promote cancer-cell death and stimulate an immune response against tumor tissue.

Intensity Therapeutics’ lead investigational product, INT230-6, is an intratumoral therapy formulated to deliver anticancer agents directly into tumors. The company is evaluating the candidate as a potential treatment for various solid tumors, both as a standalone therapy and in combination with immune checkpoint inhibitors. Its development strategy is intended to generate a local tumor response while also helping the immune system recognize and attack cancer cells elsewhere in the body.

The company’s activities are focused on research, clinical development and potential commercialization of its INTASYL-based immunotherapies. Intensity Therapeutics is headquartered in Shelton, Connecticut, and its programs are being advanced through clinical studies and research collaborations in oncology.

Key Stats

• Today's Range: $3.55 to $3.75
• 50-Day Range: $3.21 to $4.89
• 52-Week Range: $3.21 to $43.50
• Volume: 16,712 shs
• Average Volume: 17,710 shs
• Market Capitalization: $11.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Moderate Buy

Intensity Therapeutics Stock Analysis - MarketRank™

Intensity Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 248th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Intensity Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Intensity Therapeutics has a consensus price target of $7.00, representing about 92.8% upside from its current price of $3.63.

Amount of Analyst Coverage

Intensity Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Intensity Therapeutics are expected to grow in the coming year, from ($2.64) to ($1.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Intensity Therapeutics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Intensity Therapeutics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Intensity Therapeutics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.27% of the float of Intensity Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Intensity Therapeutics has a short interest ratio ("days to cover") of 2.14, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Intensity Therapeutics has recently increased by 22.22%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Intensity Therapeutics does not currently pay a dividend.

Dividend Growth

Intensity Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Intensity Therapeutics this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for INTS on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Intensity Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.60% of the stock of Intensity Therapeutics is held by insiders.

Percentage Held by Institutions

3.74% of the stock of Intensity Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:INTS
• CIK: 1567264
• Web: www.intensitytherapeutics.com
• Phone: 203 221 7381
• Fax: N/A
• Employees: 2,021
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Intensity Therapeutics: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +92.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -116.61%
• Return on Assets: -94.01%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 5.00
• Quick Ratio: 5.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.94 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 3,260,000
• Free Float: 3,017,000
• Market Cap: $11.83 million
• Optionable: Not Optionable
• Beta: 2.81